Trial Profile
Double-Blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of Single Doses of EDP239 in Hepatitis C Virus (HCV) Infected Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs EDP 239 (Primary)
- Indications Hepatitis C
- Focus Proof of concept; Therapeutic Use
- Sponsors Enanta Pharmaceuticals; Novartis
- 28 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
- 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy